Related Experiment Video
Updated: Aug 12, 2026

Knee Arthrocentesis in Adults
Published on: February 25, 2022
Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty
1College of Pharmacy, University of Georgia, Athens 30602, USA.
Insights
Low-dose warfarin daily is a cost-effective strategy for preventing deep venous thrombosis (DVT) and pulmonary embolism (PE) after total hip arthroplasty (THA). This approach offers significant cost savings compared to other pharmacoprophylaxis regimens.
Area of Science:
- Orthopedic Surgery
- Vascular Medicine
- Health Economics
Background:
- Deep venous thrombosis (DVT) and pulmonary embolism (PE) are significant risks following total hip arthroplasty (THA).
- The risk of these thromboembolic events can persist for up to 3 months post-surgery.
- Current guidelines address prophylaxis, but cost-effectiveness of different regimens requires analysis.
Purpose of the Study:
- To conduct a cost-effectiveness analysis of three pharmacoprophylaxis regimens for DVT and PE in THA patients.
- To compare the economic impact of low-dose warfarin versus enoxaparin regimens.
- To inform clinical decisions regarding extended post-discharge prophylaxis.
Main Methods:
- Cost-effectiveness analysis based on literature-reported incidences of DVT and PE post-THA.
- Evaluation of three pharmacoprophylaxis strategies: low-dose warfarin daily, enoxaparin 40 mg daily, and a combination regimen.
- Calculation of cost savings per thromboembolic event avoided for each regimen.
Main Results:
- Routine low-dose warfarin daily is projected to save $21,466.89 per avoided thromboembolic event compared to enoxaparin 40 mg daily.
- A combination of enoxaparin 40 mg for 4 days plus warfarin daily offers savings of $18,618.10 per avoided event versus enoxaparin alone.
- Warfarin-based strategies demonstrate superior cost-effectiveness.
Conclusions:
- Low-dose warfarin daily represents a highly cost-effective option for DVT and PE prophylaxis after THA.
- Combination therapy (enoxaparin + warfarin) also presents a cost-effective alternative to enoxaparin monotherapy.
- Clinicians may consider extended prophylaxis with enoxaparin and warfarin post-discharge pending further research.
Abstract:
Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA). Studies suggest that risk for developing these complications may exist for as long as 3 months following surgery. Cost-effectiveness analyses were performed on three pharmacoprophylaxis regimens administered over a 30-day period using literature-reported values for incidences of DVT and PE in patients postdischarge following THA. A cost savings of $21,466.89 will occur for each thromboembolic event avoided if low-dose warfarin daily is used routinely compared to enoxaparin 40 mg daily. Additionally, a cost savings of $18,618.10 is experienced if enoxaparin 40 mg daily for 4 days plus low-dose warfarin daily is administered versus enoxaparin 40 mg daily. Clinicians may choose to continue prophylaxis postdischarge with enoxaparin 40 mg daily for 4 days in combination with warfarin for 30 days in these patients until results of more definitive studies become available.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
